On July 3, TransThera Sciences-B rose 5.33% in regular trading, trading at HK$12.52/share, with turnover of HK$84.94 million. The stock continues its upward momentum following key R&D milestones announced on July 1.

On the news front, the company released two significant updates: its core product tinengotinib completed patient enrollment for a global multi-center registrational Phase III clinical trial for advanced cholangiocarcinoma, marking a critical step toward regulatory submission. Additionally, the company received NMPA approval to initiate a Phase II clinical trial of TT-01488 tablets in combination with anti-CD20 monoclonal antibody for the treatment of mantle cell lymphoma, further expanding its hematologic oncology pipeline.

The stock has experienced extreme volatility in recent weeks after a massive unlock event on June 23 triggered a 60% single-day decline. The company subsequently announced a share buyback plan of up to RMB 100 million on June 28. Within the Biotechnology sector, BEIGENE rose 5.21%, 3SBIO rose 4.96%, and AKESO rose 4.8%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)